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ABSTRACT 
Women with nocturia are more sensitive to desmo- 
pressin, a synthetic arginine vasopressin (AVP) ana- 
logue, with significant antidiuretic responses to des- 
mopressin orally disintegrating tablet (ODT) 25 μg, 
compared with men who require 58 μg to achieve 
similar responses. In children the current desmopres- 
sin dose recommendation to treat primary nocturnal 
enuresis (PNE) is the same for boys and girls. This 
post hoc analysis of data from a randomised, double- 
blind single-dose study of 84 children with PNE aged 
6 - 12 years explored gender differences in sensitivity 
to desmopressin in children. Following water loading 
to suppress endogenous AVP, placebo or desmopres- 
sin 30, 60, 120, 240, 360 or 480 μg was administered 
when urinary production reached >0.13 mL/min/kg. 
The endpoints of urinary osmolality and duration of 
urinary-concentrating action (DOA) (above three thres- 
holds: 125, 200 and 400 mOsm/kg) were analysed to 
compare efficacy in boys and girls, in each treatment 
group. The DOA and urinary osmolality were similar 
in both genders in the desmopressin 120 - 480 µg 
groups. Boys receiving desmopressin ODT 30 - 60 µg 
tended to increased urinary osmolality and experi-
enced 1 - 2 hours longer DOA than girls. The same 
pattern of higher values in boys compared with girls 
was seen for all measures of urinary osmolality. Con- 
clusion: In a limited sample of pre-pubertal children 
the antidiuretic response to desmopressin was largely 
similar between genders, in contrast to findings in 
adults. 
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1. INTRODUCTION 
The concept of a gender difference in renal sensitivity to 
desmopressin has been supported by several studies in 
adult patients with nocturia. In the double-blind, placebo- 
controlled NOCTUPUS studies, testing desmopressin 
tablets (0.1 mg, 0.2 mg or 0.4 mg) in 144 women [1] and 
151 men [2], a ≥50% reduction in nocturnal voids was 
achieved in 46% of women and in 34% of men; women 
had a 78% increase in mean first sleep period compared 
with a 59% increase in men. In a trial of desmopressin 
orally disintegrating tablets (ODT; Minirin® Melt), 799 
nocturia patients were randomised to placebo or desmo- 
pressin ODT (10, 25, 50 or 100 µg), for one month [3]. 
Post hoc analyses by gender demonstrated a significantly 
greater decrease in nocturnal urine volume in women at 
the lower doses of 10 µg and 25 µg compared with men 
(ED50 16.1 µg vs. 43.2 µg), suggesting significantly 
higher sensitivity to desmopressin in women [4]. A re- 
cent pharmacodynamic (PD) study of desmopressin in 
water-loaded Japanese patients with nocturia found that 
male patients required 58 µg desmopressin ODT to 
achieve a similar duration of antidiuretic action as 
achieved by female patients receiving desmopressin 25 
µg [5]. A recent meta-analysis of data from nocturia tri- 
als with desmopressin demonstrated a durable gender 
difference in sensitivity to desmopressin in favour of fe- 
males. Greater efficacy was observed with desmopressin 
ODT 25 µg in females compared with males, which en- 
dured over the long term (one year or more) [6]. Two 
physiological mechanisms behind this gender difference 
in renal sensitivity to desmopressin have been suggested, 
including the genetic X-inactivation mechanism and the *Corresponding author. 
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endogenous regulation of AVP by sex hormones [4]. 
In children with monosymptomatic nocturnal enuresis 
(MNE), current desmopressin ODT dosing recommenda- 
tions (60 - 240 µg) are the same for boys and girls. 
However, there is substantial evidence that absence of a 
nocturnal increase in AVP release is a contributing factor 
for nocturnal polyuria and enuresis [7], and that more 
boys than girls are affected by the condition. In a large 
epidemiological study, 16.1% of children aged five years 
were reported to have PNE, with double the proportion 
of boys compared with girls, 20.7% vs. 10.8%, respec- 
tively, reported to have PNE [8]. Several research papers 
have confirmed that females have significantly lower 
basal AVP levels compared to males, both in children [9] 
and in young adults [10-12]. Since no difference in urine 
volume or osmolarity was found in these studies, it is 
reasonable to assume that women and girls concentrate 
urine at lower plasma AVP levels than men and boys. 
Emerging evidence supports the hypothesis that fe- 
males have an increased sensitivity to both AVP and to 
the AVP receptor 2 (V2 receptor) specific agonist, des- 
mopressin. In adult patients with nocturia, gender-spe- 
cific dosing of desmopressin provides the clinical ad- 
vantage of minimising the risk of hyponatraemia while 
still achieving a meaningful patient benefit in reducing 
nocturnal voids [13]. However, there is a lack of evi- 
dence of gender differences in children in response to V2 
receptor stimulation, and no paediatric gender-specific 
dose recommendations have been suggested. 
Thus, the purpose of this paper is to explore possible 
gender differences in children by quantifying the urine- 
concentrating effects of desmopressin at different dose- 
levels using a gender-stratified analysis of a previously 
reported clinical study in children. While we recognise 
that a post hoc analysis is not as powerful as a primary 
analysis, ethical considerations led us to explore relevant 
data already collected prior to setting up a new interven- 
tional study in children. The current analysis also sup- 
ports power calculations for any prospective study pro- 
tocols in a paediatric population examining gender dif- 
ference in response to V2 receptor stimulation. 
2. PATIENTS AND METHODS 
Clinical data were derived from a PD double-blind, ran- 
domised, parallel-group study in children and adoles- 
cents with primary MNE [14]. 
2.1. Patients 
The study was conducted in 84 children and adolescents. 
Boys or girls aged 6 - 13 years and of normal body 
weight (body mass index [BMI] 14 - 25 kg/m2) were 
eligible for the study if primary MNE had been demon-  
strated during a run-in period. All patients were other- 
wise healthy. Exclusion criteria included evidence of 
organic urological disease, diurnal urinary incontinence, 
diabetes insipidus, ongoing urinary tract infection or any 
clinically significant disease likely to interfere with the 
evaluation; use of antibiotics, diuretics or any drug af- 
fecting urinary concentration; use of any therapy (phar- 
macological or conditioning), including desmopressin for 
PNE within 30 days of study entry; and abnormalities or 
disease of the oral cavity that might affect the release or 
absorption of the orally dispersible formulation. 
2.2. Study Design 
The study design and the clinical and safety results of 
this study have been reported in detail elsewhere [14]. 
Briefly, eligible patients were randomised to either pla- 
cebo or one of six single doses of 30, 60, 120, 240, 360 
or 480 μg desmopressin. All patients were water-loaded 
before dosing to suppress endogenous AVP. Desmo- 
pressin or placebo were administered when urinary pro- 
duction reached >0.13 mL/min/kg. Urinary volume, os- 
molality and duration of urinary-concentrating action 
(DOA) (above three threshold levels: 125, 200 and 400 
mOsm/kg) were measured. 
The study was approved by the institutional review 
board or ethics committee for each site, the Declaration 
of Helsinki was followed, and informed consent obtained 
from all patients and healthy volunteers. All data used 
are based on the ODT formulation of desmopressin.  
2.2.1. Software 
Statistical evaluation was performed using SAS (v9.2). 
2.2.2. Endpoints and Analysis 
The mean, maximum and area under curve (AUC) of 
urinary osmolality and the DOA (above three threshold 
levels: 125, 200 and 400 mOsm/kg) were compared be- 
tween genders, for each treatment group, unless n ≤ 1. 
For DOA analysis, patients with urine osmolality above 
threshold level according to these definitions, at the end 
of the measurement period, were censored at the time 
their overhydration procedure stopped. Plots of the dis- 
tributions of time-adjusted AUC of osmolality, the AUC 
of urinary osmolality for ten hours following desmo- 
pressin administration and maximum urinary osmolality 
were produced. 
Due to the limited sample size and skewed gender dis- 
tribution of PNE (the ratio of boys to girls was 3.2:1), no 
formal statistical testing was done. Any comparison 
between the two genders is therefore based on descrip- 
tive statistics, supplemented by visual evaluation of the 
graphs. 
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3. RESULTS 
3.1. Demographics 
There were no major demographic differences in the 
baseline characteristics of patients in each of the treat- 
ment groups (Table 1). Since no prospective gender 
stratification was planned, and PNE is more prevalent in 
boys, the study had a skewed gender distribution with 
more boys than girls in all treatment groups. The major- 
ity of patients were of a pre-pubertal age, with a mean 
age of nine years (range 6 - 13). No patient was over- 
weight according to the definition of BMI above 25 kg/m2. 
3.2. Duration of Urinary-Concentrating Action 
above Three Threshold Levels: 125, 200 and 
400 mOsm/kg 
In the higher dose groups, no clear difference between 
the genders in DOA was seen, although direct compari- 
son between genders in the 120 and 240 µg dose groups 
was prevented as only one girl was assigned to each of 
those dose groups. Only in the highest dose group (des- 
mopressin 480 µg) was a modestly longer mean DOA 
observed in girls compared with boys. In the low-dose 
groups (desmopressin 30 and 60 µg) boys had 1.6 - 2 
hours longer mean DOA compared with girls for all three 
threshold levels of osmolality (Table 2). 
Examining the two lowest dose groups together by gen- 
der produced a DOA distribution curve for boys that was 
rightward shifted compared with the DOA distribution 
curve for girls, indicating a modest increase in mean DOA of 
desmopressin in boys, due in part to more outliers amongst 
the boys with a DOA of around 10 - 12 hours (Figure 1). 
3.3. Mean, Maximum and AUC of Urinary 
Osmolality 
In the higher dose groups all three measurements of uri- 
 
Table 1. Demographic characteristics. 
n Age (years) BMI (kg/m2) 
Dose (µg) 
Female Male Mean SD Mean SD 
Placebo 2 10 9.3 2.1 18.7 3.5 
30 2 10 8.0 1.4 16.1 1.2 
60 5 7 9.4 2.1 17.7 3.1 
120 1 10 8.7 2.0 16.6 2.8 
240 1 11 8.4 1.7 17.0 2.0 
360 4 9 9.1 2.4 17.9 2.9 
480 5 7 9.1 1.9 16.4 1.5 
BMI, body mass index. 
Table 2. Mean duration of urinary-concentrating action in hours stratified by gender. 
    Placebo 30 µg 60 µg 120 µg 240 µg 360 µg 480 µg 
♀ 2 (0) 2 (0) 5 (0) 1 (0) 1 (1) 4 (3) 5 (3) 
n (censoreda) ♂ 10 (2) 10 (3) 7 (2) 10 (4) 11 (6) 9 (7) 7 (4) 
♀ 0.0 (0.0) 2.0 (1.6) 4.9 (2.2) 7.6b 11.6b 9.4 (1.1) 11.0 (0.8)
Mean (SD) ♂ 0.7 (1.4) 3.9 (2.1) 6.5 (2.5) 8.2 (2.0) 9.5 (1.9) 10.6 (0.7) 10.2 (0.8)
DOA 125 mOsm/kg 
Gender difference ♂ - ♀ 0.7 1.9 1.6 c c 1.2 −0.8 
♀ 2 (0) 2 (0) 5 (0) 1 (0) 1 (1) 4 (1) 5 (3) 
n (censoreda) ♂ 10 (0) 10 (0) 7 (0) 10 (3) 11 (4) 9 (4) 7 (3) 
♀ 0.0 (0.0) 0.9 (1.3) 3.8 (1.7) 7.2b 9.8b 8.8 (0.8) 9.8 (1.2) 
Mean (SD) ♂ 0.1 (0.2) 2.7 (1.7) 6.1 (2.9) 7.5 (2.2) 8.9 (1.8) 9.5 (1.8) 9.7 (1.3) 
DOA 200 mOsm/kg 
Gender difference ♂ - ♀ 0.1 1.8 2.3 c c 0.7 −0.1 
♀ 2 (0) 2 (0) 5 (0) 1 (0) 1 (1) 4 (0) 5 (2) 
n (censoreda) ♂ 10 (1) 10 (0) 7 (0) 10 (2) 11 (2) 9 (4) 7 (2) 
♀ 0.0 (0.0) 0.0 (0.0) 2.9 (1.6) 3.5b 9.8b 8.0 (1.3) 8.9 (1.8) 
Mean (SD) ♂ 0.0 (0.0) 1.6 (1.6) 4.7 (3.0) 6.1 (2.3) 8.1 (2.3) 8.6 (2.0) 8.5 (1.2) 
DOA 400 mOsm/kg 
Gender difference ♂ - ♀ 0 1.6 1.8 c c 0.6 −0.4 
aPatients with osmolality above threshold level at the time their overhydration procedure stopped were censored; bSD not calculated as n = 1; cEstimates not 
calculated as n ≤ 1. OA, duration of urinary-concentrating action; SD, standard deviation. 
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Figure 1. Distribution of duration of urine-concentrating action 
with urine osmolality above (a) 125 mOsm/kg, (b) 200 mOsm/kg 
and (c) 400 mOSm/kg in female and male patients following 
desmopressin 30 µg or 60 µg. 
 
nary osmolality were similar in both boys and girls. Girls 
did not have a numerically higher mean, maximum or 
AUC of urinary osmolality following desmopressin ad- 
ministration compared with boys in any dose groups with 
sufficient sample size (Table 3). In the low-dose groups 
(desmopressin 30 and 60 µg), boys tended to demon- 
strate a slightly greater PD response in terms of average, 
maximum and AUC of urinary osmolality compared with 
girls. 
Plots of the distributions of time-adjusted AUC of 
osmolality, the AUC of urinary osmolality for ten hours 
following desmopressin administration and maximum 
urinary osmolality indicate that across all desmopressin 
doses tested boys had a slightly longer and more pro- 
nounced magnitude of antidiuretic response (Figure 2). 
4. DISCUSSION 
The small sample size and skewed gender distribution in 
this study prohibit a direct statistical comparison between 
genders. However, based on descriptive statistics, this 
post hoc analysis found no clear difference between the 
genders in either duration or magnitude of desmopressin 
antidiuretic action in most dose groups. 
The most likely explanation for lack of a clear gender 
difference in children is that for most of the doses used in 
this study the upper asymptote of the dose-response 
curve for urine osmolality was already reached. In adults 
the desmopressin ODT ED50 for reduction in urine vol- 
ume has been estimated to be 43.2 μg and 16.1 μg in men 
and women, respectively, using a maximal response 
(Emax) dose-response model with weight-adjusted dose 
(dose/weight) and a linear placebo effect [4]. The analy- 
sis estimated the dose sensitivity to desmopressin ODT 
for women relative to men is 2.7 (95% confidence inter- 
val 1.3 - 8.1) [4]. Taking into account the mean body 
weight of approximately 28 kg in this study, the likely 
exposure to desmopressin would be proportionally 2 - 3 
times higher in children compared to adults [15]. As- 
suming linear extrapolation of desmopressin efficacy be- 
tween adults and children, desmopressin ED50 values in 
children are likely to be approximately half the magni- 
tude of ED50 values in adults. However, the desmo- 
pressin ED50 values for reduction in nocturnal urine 
volume estimated for adults were derived in patients with 
nocturia who had not been water-loaded and this study 
reports urine osmolality and DOA in water-loaded chil- 
dren following desmopressin administration. Neverthe- 
less these data indicate that any future study exploring 
gender differences in the response to desmopressin ODT 
in children should include lower doses. We suggest that 
desmopressin ODT 10 μg or a bioequivalent dose in 
other suitable formulations would be a suitable starting 
point. 
Despite the ambiguity due to the skewed gender dis- 
tribution, with more boys than girls, in the low-dose 
desmopressin ODT 30 and 60 μg groups, boys had a 1 - 
2 hours longer DOA compared with girls for all three 
threshold levels. A similar pattern was seen for mean, 
maximum and AUC of urinary osmolality, with boys 
receiving desmopressin ODT 30 and 60 µg demonstrat- 
ing higher values compared with girls. Although such a 
finding is contradictory to the expectation of greater fe- 
male renal sensitivity to desmopressin, several studies 
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Table 3. Average, maximum and AUC of urinary osmolality stratified by gender. 
   Placebo 30 µg 60 µg 120 µg 240 µg 360 µg 480 µg
♀ 2 2 5 1 1 4 5 
n ♂ 10 10 7 10 11 9 7 
♀ 37.2 136.5 381.2 569.3 844 670.2 621.9 
Mean (SD) ♂ 51.9 305.6 524.4 576.8 656.8 684.1 665.5 Average osmolality during 
action (mOsm/kg) 
Gender difference ♂ - ♀ 14.7 169.1 143.2 a a 13.9 43.6 
♀ 83.5 263 777.2 935 1049 976.8 891.8 
Mean (SD) ♂ 179.7 565.2 823.7 894.9 948.37 931.1 978.7 Maximum osmolality during action (mOsm/kg) 
Gender difference ♂ - ♀ 96.2 302.2 46.5 a a −45.7 86.9 
♀ 278.1 775.5 3047.3 4844.7 8301 7079.3 6425.5
Mean (SD) ♂ 430.5 1932.6 4152 5352.2 6609.3 7085.2 6455.8AUC of osmolality 0 - 10 hours (mOsm/kg) 
Gender difference ♂ - ♀ 152.4 1157.1 1104.7 a a 5.9 30.3 
aEstimates not calculated as n ≤ 1. AUC, area under the curve; SD, standard deviation. 
 
have demonstrated greater male sensitivity to AVP in 
young rats [16-18]. One study comparing the renal sensi- 
tivity to AVP and density of V2 receptors in young fe- 
male and male rats (aged 2 - 3 months) found that the 
young male rats had significantly greater sensitivity to 
AVP infusion and also significantly greater density of 
V2 receptors than young female rats [19]. However, a 
similar study in adult rats found the opposite result— 
female rats expressed significantly more V2 receptor 
messenger RNA and protein in the kidney than male rats, 
resulting in a greater sensitivity to V2 receptor agonist 
administration [20]. Thus, as there are no obvious rea- 
sons for the contradictory findings in these rat studies 
other than the different ages and life-stages of the ani- 
mals, it suggests that sensitivity to V2 receptor stimula- 
tion is greater in juvenile male individuals, and this in- 
verts to greater female sensitivity with sexual maturity 
and the influence of oestrogen, known to influence os- 
moregulation [21], and other sex hormones. Some pre- 
clinical studies have suggested that escape from X inac- 
tivation may alter with developmental stages or ageing, 
providing a possible mechanism for increased female 
V2R expression with age [22,23]. 
A gender difference in prevalence of MNE has been 
shown, with twice as many boys as girls affected by the 
condition [7]. Furthermore, the normal circadian increase 
in nocturnal AVP levels is absent in younger patients 
with enuresis [24]. However, it has not been reported 
whether puberty and increased levels of endogenous sex 
hormones increase AVP sensitivity to a larger degree in 
girls compared with boys. If our finding of no gender 
difference in response to V2 receptor stimulation in the 
paediatric population can be confirmed in a prospective 
study using lower doses than in our study, this will sup- 
port the hypothesis that we proposed previously [4]; a 
gender difference in sensitivity to desmopressin is absent 
in children since sex hormones are at low levels prior to 
puberty. 
Another possibility for lack of gender difference in 
children is the recently discovered age-dependent skew- 
ing of X chromosome inactivation [25]. While in general 
young females have a mosaic of cells with either the ma- 
ternal or the paternal X chromosome inactivated with a 
50:50 distribution, a deviation from this balanced ex- 
pression may occur with ageing [25]. This may clinically 
manifest as late-onset X-linked disorders. The AVPR2 
gene has known gain and loss of function mutations, 
leading to syndrome of inappropriate antidiuresis and 
nephrogenic diabetes insipidus (NDI), respectively [26]. 
A case of transient NDI associated with decreased V2 
receptor expression has been reported in a 55-year-old 
woman following surgery [27]. However, it remains to 
be shown if the AVPR2 gene located at xq-28 is subject 
to late-onset skewing of inactivation, how common such 
skewing might be and whether other mutations may con- 
tribute to V2 receptor expression differences. 
Comparative pharmacokinetic (PK)/PD studies of des- 
mopressin have only been performed in a paediatric po- 
pulation by Fjellestad-Paulsen et al. and no gender dif- 
ferences were reported [28]. As in our study, the study 
populations were predominantly male, and sample sizes 
were too small to allow gender stratification. 
Further research is therefore needed to explore poten- 
tial gender differences in response to desmopressin in a 
prospective setting, including sufficient paediatric pa- 
tients of both genders to allow for a stratified analysis. 
The current analysis supports power calculations for any 
such prospective study protocols in a paediatric popula- 
tion on gender difference in response to V2 receptor 
stimulation. Furthermore, to reduce variation in PD end- 
points due to PK variation, we recommend such a study 
to be conducted by intravenous infusion of desmopressin.  
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(a) 
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Figure 2. Distribution of urine osmolality reported as 
time adjusted AUC, (b) Emax and (c) AUC over 0 - 10 
hours in female and male patients following desmo- 
pressin 30 - 480 µg. AUC, area under the curve. 
 
A previous study designed to investigate gender differ- 
ences in desmopressin response in young adults used a 
bolus injection [29], which does not mimic steady state 
conditions, but only briefly saturates the V2 receptors. 
Therefore, we suggest a more suitable approach is to 
infuse continuously a low dose of desmopressin intrave- 
nously (to reach similar concentrations to those achieved 
using desmopressin ODT 10 μg) until steady state is 
reached and then gradually increase the dose. 
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